A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
This webinar companion guide provides information for the January 2021 Strengthening Systems of Care: Supporting People with HIV and Opioid Use Disorder following Incarceration webinar.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
This document contains slides for the September 2020 Models of Integrated Care for HIV and Opioid Use Disorder: Considerations for Community and Clinical Settings webinar.
This virtual session summary describes key takeaways from the August 2020 Let's Talk about SSPs as Essential Services conversation.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››